Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions

References

• Inamura K. Renal Cell Tumors: understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification. Int J Mol Sci. 2017;18(10):2195. doi:10.3390/ijms18102195.
   PubMed Web of Science ®Google Scholar
• Hsieh JJ, Le V, Cao D, Cheng EH, Creighton CJ. Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision. J Pathol. 2018;244(5):525–11. doi:10.1002/path.5022.
   PubMed Web of Science ®Google Scholar
• Dutcher JP. Update on the biology and management of renal cell carcinoma. J Invest Med. 2019;67(1):1–10. doi:10.1136/jim-2018-000918.
   PubMed Web of Science ®Google Scholar
• Incorvaia L, Bronte G, Bazan V, Badalamenti G, Rizzo S, Pantuso G, Natoli C, Russo A. Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma. Oncotarget. 2016;7(16):21259–21271. doi:10.18632/oncotarget.7267.
   PubMedGoogle Scholar
• Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev. 2018;70:127–137. doi:10.1016/j.ctrv.2018.07.009.
   PubMed Web of Science ®Google Scholar
• Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol. 2017;13(8):496–511. doi:10.1038/nrneph.2017.82.
   PubMed Web of Science ®Google Scholar
• Alonso-Gordoa T, García-Bermejo ML, Grande E, Garrido P, Carrato A, Molina-Cerrillo J. Targeting tyrosine kinases in renal cell carcinoma: “New Bullets Against Old Guys”. Int J Mol Sci. 2019;20(8):1901. doi:10.3390/ijms20081901.
   PubMed Web of Science ®Google Scholar
• Heidegger I, Pircher A, Pichler R. Targeting the tumor microenvironment in renal cell cancer biology and therapy. Front Oncol. 2019;9. doi:10.3389/fonc.2019.00490.
   PubMed Web of Science ®Google Scholar
• George S, Rini BI, Hammers HJ. Emerging role of combination immunotherapy in the first-line treatment of advanced renal cell carcinoma. JAMA Oncol. 2019;5(3):411. doi:10.1001/jamaoncol.2018.4604.
   PubMed Web of Science ®Google Scholar
• Roviello G, Corona SP, Nesi G, Mini E. Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter? Ther Adv Med Oncol. 2019;11:175883591986190. doi:10.1177/1758835919861905.
   Web of Science ®Google Scholar
• Braren V, Taylor JN, Pace W. Regression of metastatic renal carcinoma following nephrectomy. Urology. 1974;3(6):777–778. doi:10.1016/s0090-4295(74)80225-6.
   PubMedGoogle Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–1492. doi:10.1093/annonc/mdw168.
   PubMed Web of Science ®Google Scholar
• Badalamenti G, Fanale D, Incorvaia L, Barraco N, Listì A, Maragliano R, et al. Role of tumor-infiltrating lymphocytes in patients with solid tumors: can a drop dig a stone? Cell Immunol. 2018;103753. doi:10.1016/j.cellimm.2018.01.013.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–1813. doi:10.1056/NEJMoa1510665.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430–1437. doi:10.1200/jco.2014.59.0703.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290. doi:10.1056/NEJMoa1712126.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Choueiri TK, Motzer RJ, Aren OR, George S, Powles T, Donskov F, Harrison MR, Rodriguez Cid JRR, Ishii Y, et al. CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. J Clin Oncol. 2019;37(15_suppl):4513. doi:10.1200/JCO.2019.37.15_suppl.4513.
   Web of Science ®Google Scholar
• Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B, Kollmannsberger C, Gravis-Mescam G, Uemura M, Lee JL, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020;31(8):1030–1039. doi:10.1016/j.annonc.2020.04.010.
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–1127. doi:10.1056/NEJMoa1816714.
   PubMed Web of Science ®Google Scholar
• Incorvaia L, Fanale D, Badalamenti G, Barraco N, Bono M, Corsini LR, Galvano A, Gristina V, Listì A, Vieni S, et al. Programmed death ligand 1 (PD-L1) as a predictive biomarker for pembrolizumab therapy in patients with advanced non-small-cell lung cancer (NSCLC). Adv Ther. 2019;36(10):2600–2617. doi:10.1007/s12325-019-01057-7.
   PubMed Web of Science ®Google Scholar
• Cottrell TR, Taube JM. PD-L1 and emerging biomarkers in immune checkpoint blockade therapy. Cancer J. 2018;24(1):41–46. doi:10.1097/ppo.0000000000000301.
   PubMed Web of Science ®Google Scholar
• Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108(3):479–485. doi:10.1038/bjc.2012.581.
   PubMed Web of Science ®Google Scholar
• Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JLP, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15(8):457–472. doi:10.1038/nrc3973.
   PubMed Web of Science ®Google Scholar
• Benyamine A, Le Roy A, Mamessier E, Gertner-Dardenne J, Castanier C, Orlanducci F, Pouyet L, Goubard A, Collette Y, Vey N, et al. BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia. OncoImmunology. 2016;5(10):e1146843. doi:10.1080/2162402x.2016.1146843.
   PubMed Web of Science ®Google Scholar
• Benyamine A, Loncle C, Foucher E, Blazquez J-L, Castanier C, Chrétien A-S, Modesti M, Secq V, Chouaib S, Gironella M, et al. BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). OncoImmunology. 2017;7(1):e1372080. doi:10.1080/2162402x.2017.1372080.
   PubMed Web of Science ®Google Scholar
• Bian B, Fanale D, Dusetti N, Roque J, Pastor S, Chretien A-S, Incorvaia L, Russo A, Olive D, Iovanna J, et al. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. OncoImmunology. 2019;8(4):e1561120. doi:10.1080/2162402x.2018.1561120.
   PubMed Web of Science ®Google Scholar
• Frigola X, Inman BA, Lohse CM, Krco CJ, Cheville JC, Thompson RH, Leibovich B, Blute ML, Dong H, Kwon ED, et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011;17(7):1915–1923. doi:10.1158/1078-0432.ccr-10-0250.
   PubMed Web of Science ®Google Scholar
• Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G, Le Gouill S, Haioun C, Tarte K, Lamy T, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia. 2014;28(12):2367–2375. doi:10.1038/leu.2014.137.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang H, Chen H, Wang W-D, Chen X-Q, Geng Q-R, Xia Z-J, Lu Y. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget. 2015;6(38):41228–41236. doi:10.18632/oncotarget.5682.
   PubMedGoogle Scholar
• Finkelmeier F, Canli Ö, Tal A, Pleli T, Trojan J, Schmidt M, Kronenberger B, Zeuzem S, Piiper A, Greten FR. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Eur J Cancer. 2016;59:152–159. doi:10.1016/j.ejca.2016.03.002.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Iwasa S, Sasaki Y, Shoji H, Honma Y, Takashima A, Okita NT, Kato K, Hamaguchi T, Yamada Y, et al. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. J Cancer Res Clin Oncol. 2016;142(8):1727–1738. doi:10.1007/s00432-016-2184-6.
   PubMed Web of Science ®Google Scholar
• Okuma Y, Hosomi Y, Nakahara Y, Watanabe K, Sagawa Y, Homma S. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Lung Cancer. 2017;104:1–6. doi:10.1016/j.lungcan.2016.11.023.
   PubMed Web of Science ®Google Scholar
• Shigemori T, Toiyama Y, Okugawa Y, Yamamoto A, Yin C, Narumi A, Ichikawa T, Ide S, Shimura T, Fujikawa H, et al. Soluble PD-L1 expression in circulation as a predictive marker for recurrence and prognosis in gastric cancer: direct comparison of the clinical burden between tissue and serum PD-L1 expression. Ann Surg Oncol. 2018;26(3):876–883. doi:10.1245/s10434-018-07112-x.
   PubMed Web of Science ®Google Scholar
• Han X, Gu Y-K, Li S-L, Chen H, Chen M-S, Cai -Q-Q, Deng H-X, Zuo M-X, Huang J-H. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma. J Cancer Res Clin Oncol. 2018;145(2):303–312. doi:10.1007/s00432-018-2758-6.
   PubMed Web of Science ®Google Scholar
• Ha H, Nam A-R, Bang J-H, Park J-E, Kim T-Y, Lee K-H, Han S-W, Im S-A, Kim T-Y, Bang Y-J. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Oncotarget. 2016;7(47):76604–76612. doi:10.18632/oncotarget.12810.
   PubMedGoogle Scholar
• Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, Rodig S, Li J, Wu X, Butterfield LH, et al. Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. Cancer Immunol Res. 2017;5(6):480–492. doi:10.1158/2326-6066.cir-16-0329.
   PubMed Web of Science ®Google Scholar
• Incorvaia L, Badalamenti G, Rinaldi G, Iovanna JL, Olive D, Swayden M, Terruso L, Vincenzi B, Fulfaro F, Bazan V, et al. Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? Ther Adv Med Oncol. 2019;11:175883591984887. doi:10.1177/1758835919848872.
   Web of Science ®Google Scholar
• Wang Q, Zhang J, Tu H, Liang D, Chang DW, Ye Y, Wu X. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients. J ImmunoTher Cancer. 2019;7(1). doi:10.1186/s40425-019-0810-y.
   Web of Science ®Google Scholar
• Kushlinskii NE, Gershtein ES, Morozov AA, Goryacheva IO, Filipenko ML, Alferov AA, Bezhanova SD, Bazaev VV, Kazantseva IA. Soluble ligand of the immune checkpoint receptor (sPD-L1) in blood serum of patients with renal cell carcinoma. Bull Exp Biol Med. 2019;166(3):353–357. doi:10.1007/s10517-019-04349-8.
   PubMed Web of Science ®Google Scholar
• Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, Leroy K, Boudou-Rouquette P, Tlemsani C, Khoudour N. Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case-control study. Cancers. 2020;12(2):473. doi:10.3390/cancers12020473.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Lee J-L, Szczylik C, Donskov F, Malik J, Alekseev BY, Larkin JMG, Matveev VB, Gafanov RA, Tomczak P, et al. Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427.. J Clin Oncol. 2018;36(15_suppl):4500. doi:10.1200/JCO.2018.36.15_suppl.4500.
   Web of Science ®Google Scholar
• Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Beuselinck B, Amin A, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20(10):1370–1385. doi:10.1016/s1470-2045(19)30413-9.
   PubMed Web of Science ®Google Scholar